In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Vaks, Lilach ^a   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDES; ANIMAL EXPERIMENTATION; ANTI-BACTERIAL; CHEMICAL COMPONENT; CONTROLLED RELEASE; DRUG DELIVERY SYSTEM; FILAMENTOUS PHAGE; IMMUNOGENICITY; IN-VIVO; NANOMEDICINES; NANOMETRICS; PATHOGENIC BACTERIUM; PHAGE PARTICLES; POORLY WATER-SOLUBLE DRUGS; TARGET CELLS; TUMOR CELLS;

ANTIBIOTICS; BLOOD; DRUG DELIVERY; ESCHERICHIA COLI; GENETIC ENGINEERING; MAMMALS; SOLUBILITY; WATER INJECTION;

MEDICAL NANOTECHNOLOGY;

AMINOGLYCOSIDE ANTIBIOTIC AGENT; NANOCARRIER; NEOMYCIN PLUS CHLORAMPHENICOL; PRODRUG; UNCLASSIFIED DRUG; DRUG CARRIER; NEOMYCIN;

ANIMAL EXPERIMENT; ARTICLE; COLONY FORMING UNIT; DRUG BLOOD LEVEL; DRUG CARRYING FILAMENTOUS BACTERIOPHAGE NANOMEDICINE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; INJECTION; MOUSE; NANOMEDICINE; NONHUMAN; ANIMAL; BACTERIOPHAGE; CHEMISTRY;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; FILAMENTOUS BACTERIOPHAGE; MUS;

ANIMALS; BACTERIOPHAGES; DRUG CARRIERS; MICE; NANOMEDICINE; NEOMYCIN;

EID: 83655211777     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-58     Document Type: Article

References (23)

1. Yacoby I, Shamis M, Bar H, Shabat D, Benhar I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrobial agents and chemotherapy 2006, 50:2087-2097. 10.1128/AAC.00169-06, 1479106, 16723570.
2. Yacoby I, Bar H, Benhar I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrobial agents and chemotherapy 2007, 51:2156-2163. 10.1128/AAC.00163-07, 1891362, 17404004.
3. Mishra D, Mishra PK, Dabadghao S, Dubey V, Nahar M, Jain NK. Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine: nanotechnology, biology, and medicine 2010, 6:110-118.
4. Singh S. Nanomedicine-nanoscale drugs and delivery systems. Journal of nanoscience and nanotechnology 2010, 10:7906-7918. 10.1166/jnn.2010.3617, 21121278.
5. Yacoby I, Benhar I. Targeted anti bacterial therapy. Infectious disorders drug targets 2007, 7:221-229. 10.2174/187152607782109998, 17897058.
6. Carlton RM, Noordman WH, Biswas B, de Meester ED, Loessner MJ. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 2005, 43:301-312. 10.1016/j.yrtph.2005.08.005, 16188359.
7. Krag DN, Fuller SP, Oligino L, Pero SC, Weaver DL, Soden AL, Hebert C, Mills S, Liu C, Peterson D. Phage-displayed random peptide libraries in mice: toxicity after serial panning. Cancer chemotherapy and pharmacology 2002, 50:325-332. 10.1007/s00280-002-0489-4, 12357308.
8. Turton JA, Andrews CM, Havard AC, Williams TC. Studies on the haemotoxicity of chloramphenicol succinate in the Dunkin Hartley guinea pig. International journal of experimental pathology 2002, 83:225-238. 2517684, 12641819.
9. van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 2010, 28:2174-2185. 10.1016/j.vaccine.2009.12.059, 2830289, 20056188.
10. van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 2006, 24:4188-4200. 10.1016/j.vaccine.2006.01.001, 1974903, 16488517.
11. Sartorius R, Pisu P, D'Apice L, Pizzella L, Romano C, Cortese G, Giorgini A, Santoni A, Velotti F, De Berardinis P. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J Immunol 2008, 180:3719-3728.
12. Sunagar R, Patil SA, Chandrakanth RK. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Research in microbiology 2010, 161:854-860. 10.1016/j.resmic.2010.09.011, 20868746.
13. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. International journal of molecular medicine 2006, 17:347-355.
14. Solomon B. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine 2007, 25:3053-3056. 10.1016/j.vaccine.2007.01.069, 17287054.
15. Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology 2000, 269:47-53. 10.1006/viro.2000.0185, 10725197.
16. Weissig VV, Babich J, Torchilin VV. Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. Colloids Surf B Biointerfaces 2000, 18:293-299. 10.1016/S0927-7765(99)00155-1, 10915951.
17. Marik J, Tartis MS, Zhang H, Fung JY, Kheirolomoom A, Sutcliffe JL, Ferrara KW. Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol 2007, 34:165-171. 10.1016/j.nucmedbio.2006.12.004, 1849971, 17307124.
18. Romberg B, Metselaar JM, Baranyi L, Snel CJ, Bunger R, Hennink WE, Szebeni J, Storm G. Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. International journal of pharmaceutics 2007, 331:186-189. 10.1016/j.ijpharm.2006.11.018, 17145145.
19. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. International journal of pharmaceutics 2005, 300:125-130. 10.1016/j.ijpharm.2005.06.007, 16046256.
20. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2008, 22:315-329.
21. Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL. Biodistribution of filamentous phage peptide libraries in mice. Molecular biology reports 2004, 31:121-129.
22. Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 2002, 293:182-191. 10.1006/viro.2001.1254, 11853411.
23. Housby JN, Mann NH. Phage therapy. Drug discovery today 2009, 14:536-540. 10.1016/j.drudis.2009.03.006, 19508915.